G7 THERAPEUTICS
G7 Therapeutics utilises proprietary approaches to stabilise G protein-coupled receptors (GPCRs) and enables novel structure-based drug development strategies to be applied for the design of highly selective small molecules or biologics targeting GPCRs.
G7 THERAPEUTICS
Social Links:
Industry:
Pharmaceutical
Founded:
2013-01-01
Address:
Zürich, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.g7therapeutics.com
Total Employee:
1+
Status:
Active
Contact:
+44 (0)1707 358 628
Email Addresses:
[email protected]
Technology used in webpage:
SPF LetsEncrypt Apache Unified Layer Logic Boxes
Official Site Inspections
http://www.g7therapeutics.com
- Host name: 172.67.135.152
- IP address: 172.67.135.152
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "G7 Therapeutics"
G1 Therapeutics, Inc. | LinkedIn
G1 Therapeutics, Inc. | 16,504 followers on LinkedIn. Our mission is to discover, develop and deliver next generation cancer therapies. | G1 Therapeutics, Inc. is a wholly owned subsidiary …See details»
G1 Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Phone Number +1 919 213 9835 G1 Therapeutics, Inc. is a commercial-stage oncology firm focused on the research and marketing of next-generation anticancer treatments.See details»
Pharmacosmos Group and G1 Therapeutics Announce Successful …
Sep 18, 2024 Following the closing of the tender offer, on September 18, 2024 Purchaser merged with and into G1 Therapeutics, with G1 Therapeutics continuing as the surviving …See details»
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan ...
Jan 3, 2024 RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced …See details»
Pharmacosmos Group to Acquire G1 Therapeutics - Yahoo Finance
Aug 7, 2024 - Business Combination Expected to Provide Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Optimal Access to G1’s COSELA® (trilaciclib), the First and …See details»
G1 Therapeutics Announces Appointment of Andrew Perry as …
Aug 2, 2021 Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2021 (GLOBE NEWSWIRE) -- G1 …See details»
FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The
Feb 13, 2021 A live and archived webcast will be available on the Events & Presentations page of the company’s website: www.g1therapeutics.com. The webcast will be archived on the same page for 90 days ...See details»
G1 Therapeutics Announces Chief Executive Officer Succession Plan
Sep 30, 2020 - Mark Velleca, M.D., Ph.D., G1’s first Chief Executive Officer, to serve as senior advisor and remain member of the G1 Board of Directors - Jack Bailey to succeed Dr. Velleca …See details»
G1 Therapeutics Announces Addition of Alicia Secor to Board of ...
Jun 18, 2021 RESEARCH TRIANGLE PARK, N.C., June 18, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced …See details»
G1 Therapeutics Announces Chief Executive Officer Succession Plan
Sep 30, 2020 G1 Therapeutics, Inc. (Nasdaq: GTHX), a company whose mission is to deliver innovative therapies that improve the lives of people with cancer, today announced that …See details»
G1 Therapeutics Provides Corporate Update at the 42nd
Jan 8, 2024 G1 Therapeutics provides Corporate and Clinical Update at the 42md Annual J.P. Morgan healthcare conference. ...See details»
G1 Therapeutics Announces Acceptance and Priority Review of …
Aug 17, 2020 For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics. Forward-Looking Statements This press release contains forward …See details»
Pharmacosmos Group to Acquire G1 Therapeutics - Morningstar
Aug 7, 2024 By combining our existing colleagues with the great team at G1 Therapeutics, we will meaningfully expand our organization serving oncologists in the US. This will enable …See details»
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in …
Jun 24, 2024 - PRESERVE 2 Did Not Achieve Statistical Significance in the Primary Endpoint of Overall Survival (OS) in the Intent-to-Treat (ITT) Population - - The Company Will Focus its …See details»
FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The
Feb 13, 2021 G1 shares our organization’s goal to improve the quality of life of those diagnosed with lung cancer and to transform survivorship among people living with this insidious disease.See details»
Pharmacosmos Group and G1 Therapeutics Announce
Sep 18, 2024 For additional information, please visit www.g1therapeutics.com and follow us on X (formerly known as Twitter) @G1Therapeutics and LinkedIn. G1 Therapeutics ...See details»
G1 Therapeutics Announces Acceptance and Priority Review of …
Aug 17, 2020 \- PDUFA action date of February 15, 2021 assigned by U.S. Food and Drug Administration \- Priority Review for trilaciclib is based on positive data from three randomized …See details»
G1 Therapeutics and Simcere Announce Exclusive License …
Aug 3, 2020 Lung cancer is the most common cancer worldwide, with small cell lung cancer accounting for approximately 15% of all lung cancer cases. According to the World Health …See details»
G1 Therapeutics Receives Fast Track Designation from U.S. Food …
Jul 19, 2021 RESEARCH TRIANGLE PARK, N.C., July 19, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced …See details»